JP2011504092A - 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体 - Google Patents

血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体 Download PDF

Info

Publication number
JP2011504092A
JP2011504092A JP2010530629A JP2010530629A JP2011504092A JP 2011504092 A JP2011504092 A JP 2011504092A JP 2010530629 A JP2010530629 A JP 2010530629A JP 2010530629 A JP2010530629 A JP 2010530629A JP 2011504092 A JP2011504092 A JP 2011504092A
Authority
JP
Japan
Prior art keywords
vegf
antibody
angiogenic
antibodies
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010530629A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011504092A5 (https=
Inventor
デイビッド オー． ベイツ，
スティーブン ジェイ． ハーパー，
ミリアム ワイ． マンゲラス，
メナチェム ゼーヴィ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bristol
Original Assignee
University of Bristol
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bristol filed Critical University of Bristol
Publication of JP2011504092A publication Critical patent/JP2011504092A/ja
Publication of JP2011504092A5 publication Critical patent/JP2011504092A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010530629A 2007-10-25 2008-10-26 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体 Pending JP2011504092A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98243807P 2007-10-25 2007-10-25
PCT/IL2008/001410 WO2009053987A1 (en) 2007-10-25 2008-10-26 Antibodies specific to pro-angiogenic isoforms of vascular endothelial growth factor (vegf)

Publications (2)

Publication Number Publication Date
JP2011504092A true JP2011504092A (ja) 2011-02-03
JP2011504092A5 JP2011504092A5 (https=) 2012-11-15

Family

ID=40385456

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010530629A Pending JP2011504092A (ja) 2007-10-25 2008-10-26 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体

Country Status (7)

Country Link
US (1) US8592563B2 (https=)
EP (1) EP2203480A1 (https=)
JP (1) JP2011504092A (https=)
CN (1) CN101970486A (https=)
AU (1) AU2008315414A1 (https=)
CA (1) CA2703154A1 (https=)
WO (1) WO2009053987A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528693A (ja) * 2011-06-15 2014-10-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ヒトｅｐｏ受容体抗体及び使用方法
WO2016194708A1 (ja) * 2015-05-29 2016-12-08 国立大学法人名古屋大学 尿中ＶＥＧＦ－Ａ１６５ｂを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018260B1 (ru) 2006-09-29 2013-06-28 Онкомед Фармасьютикалз, Инк. Антитела к дельта-подобному лиганду 4 человека и их применение
JP2012525149A (ja) 2009-04-27 2012-10-22 オンコメッド ファーマシューティカルズ インコーポレイテッド ヘテロ多量体分子を作製するための方法
ES2700450T3 (es) 2009-10-16 2019-02-15 Oncomed Pharm Inc Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores
US20130034861A1 (en) * 2009-12-21 2013-02-07 Mayo Foundation For Medical Education And Research Early marker of proteinuria in patients treated with an anti-vegf treatment
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
US9599620B2 (en) 2012-10-31 2017-03-21 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
WO2014117053A1 (en) * 2013-01-27 2014-07-31 The Cleveland Clinic Foundation Anti-angiogenic vegf-ax isoform
WO2016070051A2 (en) 2014-10-31 2016-05-06 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
EP3353204B1 (en) 2015-09-23 2023-10-18 Mereo BioPharma 5, Inc. Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513111A (ja) * 1997-03-03 2001-08-28 ベス・イスラエル・デイーコネス・メデイカル・センター 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート
WO2005007198A2 (en) * 2003-07-08 2005-01-27 Attogen, Inc. Design of disease specific agents for diagnostics and therapeutics based on the protein isoform of vegf, her-2, psa
JP2005502333A (ja) * 2001-08-01 2005-01-27 ユニバーシティ　オブ　ブリストル 増殖因子イソ型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US7667004B2 (en) 2001-04-17 2010-02-23 Abmaxis, Inc. Humanized antibodies against vascular endothelial growth factor
AU2006242449A1 (en) * 2005-04-29 2006-11-09 (Osi) Eyetech, Inc. VEGF variants
US20080031815A1 (en) * 2006-07-27 2008-02-07 Xiaoyuan Chen Pet imaging of vascular endothelial growth factor receptor (VEGFR), compositions for VEGF cancer imaging, and methods of VEGF cancer imaging
GB0704678D0 (en) 2007-03-09 2007-04-18 Univ Bristol Pro- and anti-angiogenic treatments

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001513111A (ja) * 1997-03-03 2001-08-28 ベス・イスラエル・デイーコネス・メデイカル・センター 腫瘍付随血管（ｔｕｍｏｒ−ａｓｓｏｃｉａｔｅｄ ｂｌｏｏｄ ｖｅｓｓｅｌｓ）上の血管透過因子の複数のエピトープに結合する同時インビボイムノコンジュゲート
JP2005502333A (ja) * 2001-08-01 2005-01-27 ユニバーシティ　オブ　ブリストル 増殖因子イソ型
WO2005007198A2 (en) * 2003-07-08 2005-01-27 Attogen, Inc. Design of disease specific agents for diagnostics and therapeutics based on the protein isoform of vegf, her-2, psa

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013037826; Ｃａｎｃｅｒ　Ｒｅｓ．，　２００４，　６４（２１），　ｐｐ．７８２２-７８３５ *
JPN6013037827; Ｄｉａｂｅｔｏｌｏｇｉａ，　２００５，　４８（１１），　ｐｐ．２４２２-２４２７ *
JPN6013037828; Ｂｒ．　Ｊ．　Ｃａｎｃｅｒ，　２００７，　９７（２），　ｐｐ．２２３-２３０　（Ｅｐｕｂ　２００７　Ｊｕｎ　２６） *
JPN6013037829; Ｍｏｌ．　Ｖｉｓ．，　２００６，　１２，　ｐｐ．６２６-６３２ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528693A (ja) * 2011-06-15 2014-10-30 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ヒトｅｐｏ受容体抗体及び使用方法
WO2016194708A1 (ja) * 2015-05-29 2016-12-08 国立大学法人名古屋大学 尿中ＶＥＧＦ－Ａ１６５ｂを指標とした腎機能の検査方法及び検査装置、腎機能の検査装置として機能させるためのプログラム及び記録媒体

Also Published As

Publication number Publication date
AU2008315414A1 (en) 2009-04-30
EP2203480A1 (en) 2010-07-07
CN101970486A (zh) 2011-02-09
WO2009053987A1 (en) 2009-04-30
US20100272733A1 (en) 2010-10-28
CA2703154A1 (en) 2009-04-30
US8592563B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
JP2011504092A (ja) 血管内皮増殖因子（ｖｅｇｆ）の血管新生誘発性アイソフォームに特異的な抗体
JP6591428B2 (ja) 癌治療のためのｐｄ−１拮抗薬およびｖｅｇｆｒ阻害剤の組み合わせ
JP6000427B2 (ja) 抗エンドグリン抗体及び抗ｖｅｇｆ剤を用いる癌の併用療法
KR101320198B1 (ko) 신생물의 치료를 위한 조성물 및 방법
CN112203695B (zh) 用基于铂的试剂和抗组织因子抗体-药物偶联物的组合治疗癌症的方法
KR20200034817A (ko) 항-ｖｅｇｆ 항체를 사용한 치료
JP2015502355A (ja) 癌治療のための抗ｃｅａｃａｍ１組換え型抗体
MX2012009554A (es) Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
KR20120096401A (ko) 아주반트 암 요법
CN110382532A (zh) 抗g-csf抗体及其用途
US11081235B2 (en) Extracellular matrix metalloproteinase inducer (EMMPRIN) peptides and binding antibodies
KR20210066837A (ko) 암 치료를 위한 pd-1 안타고니스트, atr 억제제 및 백금화제의 조합
EP3789401A1 (en) Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers
WO2011119656A1 (en) Anti-angiogenesis therapy for treating abdominal aortic aneurysm
US20240366777A1 (en) Anti-folate receptor conjugate combination therapy with bevacizumab
US20240408228A1 (en) Anti-folate receptor conjugate cancer therapy
KR102207221B1 (ko) 도펠-타겟팅 분자를 이용한 병리학적 신생혈관 생성을 억제하는 방법
HK40045175A (en) Methods of treating cancer with a combination of a platinum-based agent and an anti-tissue factor antibody-drug conjugate
HK1213177A1 (zh) 抗-vegf抗体与化学治疗联合用於治疗乳腺癌的应用
HK1172839A (en) Anti-angiogenesis therapy for the treatment of previously treated breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110930

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120919

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130731

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131227